*Correspondence: Fernando Lizcano, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
10.1007/s11065-012-9199-9 [DOI] [PubMed] [Google Scholar] Massart R., Mongeau R., Lanfumey L
the data from these two large, well-powered clinical trials will provide robust evidence on the cardiovascular and metabolic benefits of tirzepatide, potentially expanding the treatment options for adults with T2DM, obesity, and related cardiovascular complications [7] (Clinical Traials.gov)
The SUSTAIN-6 Trial (Once-Weekly Semaglutide) The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) consisted of 3297 people living with T2DM, 83% with established cardiovascular disease, receiving once-weekly semaglutide (0.5 and 1.0 mg) or placebo
Multani mitti 1 tsp
One shared patient story for the obesity physician, the nutritionist, and the psychologist instead of three disconnected versions of the same person
